Castellan Group Invests $8.54 Million in TG Therapeutics, Inc. (NASDAQ:TGTX)

Castellan Group acquired a new stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 283,679 shares of the biopharmaceutical company's stock, valued at approximately $8,539,000. TG Therapeutics comprises about 3.7% of Castellan Group's investment portfolio, making the stock its 3rd biggest holding. Castellan Group owned approximately 0.18% of TG Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. SG Americas Securities LLC grew its position in shares of TG Therapeutics by 181.9% in the third quarter. SG Americas Securities LLC now owns 23,614 shares of the biopharmaceutical company's stock valued at $552,000 after purchasing an additional 15,238 shares in the last quarter. Valeo Financial Advisors LLC bought a new position in TG Therapeutics in the 3rd quarter worth about $239,000. ORG Wealth Partners LLC purchased a new position in TG Therapeutics during the 3rd quarter valued at about $53,000. Creative Planning increased its position in shares of TG Therapeutics by 19.2% during the third quarter. Creative Planning now owns 55,832 shares of the biopharmaceutical company's stock valued at $1,306,000 after buying an additional 8,993 shares during the period. Finally, NBC Securities Inc. lifted its holdings in shares of TG Therapeutics by 58.9% in the third quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company's stock worth $30,000 after buying an additional 485 shares in the last quarter. Institutional investors own 58.58% of the company's stock.

Insider Buying and Selling

In other TG Therapeutics news, CFO Sean A. Power sold 10,021 shares of the firm's stock in a transaction on Monday, January 6th. The stock was sold at an average price of $28.53, for a total transaction of $285,899.13. Following the completion of the transaction, the chief financial officer now owns 660,611 shares of the company's stock, valued at approximately $18,847,231.83. This trade represents a 1.49 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 10.50% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of analysts recently weighed in on TGTX shares. TD Cowen assumed coverage on shares of TG Therapeutics in a report on Tuesday, October 29th. They set a "buy" rating and a $50.00 target price on the stock. The Goldman Sachs Group upped their price target on shares of TG Therapeutics from $20.00 to $22.00 and gave the stock a "neutral" rating in a report on Tuesday, November 5th. HC Wainwright restated a "buy" rating and set a $55.00 target price on shares of TG Therapeutics in a research report on Wednesday, January 15th. StockNews.com cut TG Therapeutics from a "hold" rating to a "sell" rating in a report on Friday, January 31st. Finally, JPMorgan Chase & Co. lifted their target price on shares of TG Therapeutics from $30.00 to $43.00 and gave the stock an "overweight" rating in a research note on Monday, November 25th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $40.67.

TG Therapeutics Trading Down 0.1 %

TG Therapeutics stock traded down $0.02 during mid-day trading on Monday, reaching $30.71. 1,179,306 shares of the company traded hands, compared to its average volume of 2,274,709. The firm's 50 day moving average price is $31.15 and its 200 day moving average price is $27.42. TG Therapeutics, Inc. has a 52-week low of $12.84 and a 52-week high of $36.84. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. The firm has a market capitalization of $4.78 billion, a price-to-earnings ratio of -307.07 and a beta of 2.26.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.